
Draig Therapeutics Emerges With $140M for Clinical Tests of Novel Neuropsychiatric Drugs
Neuropsychiatric disorders need new drugs that offer improvement in safety and efficacy over currently available medicines. Draig Therapeutics has emerged from stealth with $140 million to support mid-stage testing of a lead program that it believes may …